Alexandria (ARE): Cheap Below Book, But the 45% Dividend Cut Says the Market Isn't Wrong

Alexandria Real Estate Equities looks like the kind of stock a value investor is supposed to buy without thinking too hard. The shares trade around $51, roughly 42% below their 52-week high, at less than half of book value, with a 5.6% dividend yield and an even lower multiple of its tenant-rent earnings. The reflexive read is that the market has panicked and left a top-tier life-science landlord on the table at a giveaway price.

That read is worth testing before anyone acts on it, because the market is not always wrong. And in this case the single most important fact isn't the price at all — it's the dividend. In late 2025, Alexandria cut its quarterly payout from $1.32 to $0.72, a 45% reduction that broke a 14-year streak of annual increases. Management said the move would preserve roughly $410 million a year for its 2026 capital plan. A company does not cut a dividend it could still afford to pay. That one decision is management's own admission that the old, higher payout was not sustainable, and it reframes everything the "bargain" headline is selling.

The cheapness is earned, not a mispricing

The best way to see what the stock price is actually telling you is to follow the cash-flow meter REIT investors actually use — funds from operations, or FFO, which adds back the non-cash depreciation on the buildings. On a per-share, as-adjusted basis, Alexandria earned $9.47 in 2024 and $9.01 in 2025. For 2026, management guided to a midpoint of $6.40. Round it up and FFO per share has fallen roughly a third in two years, and the decline isn't finished: guidance assumes same-property net operating income falls 8.5% to 10.5% this year after dropping 11.5% in the first half.

The deterioration underneath is unmistakable. Occupancy sat at 86.9% at mid-2026, down from the high-93% level a year earlier. Same-property occupancy for the first half was 88.2% against 93.5% a year ago, and renewal rents were negotiated at negative rental-rate changes. Reported results are even uglier — a $1.4 billion net loss for 2025, driven by non-cash property impairments.

So the stock's cheap multiple is not a free mispricing. The market is largely pricing in a business whose rental cash flow has genuinely contracted. This is the difference between a bargain and a repricing: a bargain is a durable stream trading below what it's worth, while a repricing is a market correctly marking a falling stream down. Alexandria has mattered plenty of the former in its history — in 2022 it was pre-leasing nearly 80% of a massive construction pipeline to tenants like Moderna and Bristol-Myers Squibb. It is not that company today.

Why this still isn't a solvency trap

Here is where the bear case runs into the balance sheet, and it's a real reason for caution about reflexively shorting or dismissing the name. Alexandria survives this downturn with room to spare. The new $0.72 quarterly dividend runs about $2.88 a year, roughly 45% of the $6.40 FFO midpoint of 2026 guidance — comfortably covered, unlike the payout it replaced. Liquidity stands at $3.6 billion, and a $5 billion credit revolver was recently extended to 2032 at a reduced borrowing spread.

Most importantly, the debt load is not coming due. Only about 6% of total debt matures through 2028, and the weighted-average remaining term is roughly 9.7 years. Management is also doing the work a deleveraging requires, targeting about $2.9 billion in dispositions and other capital sources in 2026, with roughly $1.675 billion earmarked for debt reduction. A company that can cut its dividend, open a long runway on its maturities, and sell assets to pay down borrowings is not heading toward insolvency.

That matters, because from a survival standpoint it separates Alexandria from a genuinely distressed E&P or broken-balance-sheet name where cheapness is a trap. The question here is not whether the company makes it. It is whether the cash flows stop falling before the leverage becomes a problem.

The lever that decides it

Set survival aside and the balance sheet still carries real tension. Net debt and preferred stock stood at about 7.0x adjusted EBITDA on a second-quarter annualized basis — high for a REIT of this quality — with a target of 5.6x to 6.2x by year-end. Management's own long-term goal is the mid-5x range. That leverage is only tolerable while the lease-up engines are running, and right now those engines are just starting to turn over.

There is a genuine green shoot in the numbers. Alexandria leased more than a million square feet in the second quarter, up 60% from the first, and a chunk of it was previously vacant or newly built space — the second-highest absorption of that kind since 2024. If that inflection holds and vacancies keep leasing up, FFO stabilizes, net operating income stops bleeding, and a stock at roughly eight times forward FFO on a premier life-science portfolio looks genuinely cheap. If it doesn't, another year of 8%–10% same-store NOI declines pushes leverage higher, and "cheap" becomes cheaper for a reason.

That is the honest version of this setup, and it's why I would not call it a bargain in the classic value sense. A bargain demands a stable or growing stream bought below what it's worth, with a margin of safety against being wrong. Alexandria offers a well-covered new dividend, a fortress balance-sheet runway, and a real valuation discount — but the stream is still shrinking and the leverage is at the high end. The dividend cut is the tell: management did not trust its own payout to ride this out. Buying here is a bet on the lease-up recovery arriving before the cash-flow decline and the debt work do something worse. That can pay off handsomely, but it is a turnaround at a discount, not a bargain, and the two are not the same thing.